skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Role of olmesartan in combination therapy in blood pressure control and vascular function

Review

(2415) Views  (801) Full article downloads

Authors: Carlos M Ferrario, Ronald D Smith

Published Date August 2010 Volume 2010:6 Pages 701 - 709
DOI: http://dx.doi.org/10.2147/VHRM.S6663

Carlos M Ferrario, Ronald D Smith

Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA

Abstract: Angiotensin receptor blockers have emerged as a first-line therapy in the management of hypertension and hypertension-related comorbidities. Since national and international guidelines have stressed the need to control blood pressure to <140/90 mmHg in uncomplicated hypertension and <130/80 mmHg in those with associated comorbidities such as diabetes or chronic kidney disease, these goal blood pressures can only be achieved through combination therapy. Of several drugs that can be effectively combined to attain the recommended blood pressure goals, fixed-dose combinations of angiotensin receptor blockers and the calcium channel blocker amlodipine provide additive antihypertensive effects associated with a safe profile and increased adherence to therapy. In this article, we review the evidence regarding the beneficial effects of renin–angiotensin system blockade with olmesartan medoxomil and amlodipine in terms of blood pressure control and improvement of vascular function and target organ damage.

Keywords: amlodipine, angiotensin receptor blockers, angiotensin-converting enzyme 2, hypertension, renin–angiotensin system




 

Other articles by Dr Carlos Ferrario



Readers of this article also read:

Candesartan cilexetil in the treatment of chronic heart failure
Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil
Amlodipine and valsartan as components of a rational and effective fixed-dose combination
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice
Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
Spillover adherence effects of fixed-dose combination HIV therapy
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University